Puma Biotechnology, Inc. $PBYI Holdings Lifted by Sei Investments Co.

Sei Investments Co. increased its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 18.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 508,182 shares of the biopharmaceutical company’s stock after acquiring an additional 78,257 shares during the period. Sei Investments Co. owned about 1.00% of Puma Biotechnology worth $3,247,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. State of Wyoming increased its holdings in shares of Puma Biotechnology by 42.6% in the 1st quarter. State of Wyoming now owns 75,808 shares of the biopharmaceutical company’s stock valued at $484,000 after purchasing an additional 22,653 shares during the period. Dimensional Fund Advisors LP grew its position in Puma Biotechnology by 7.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,436,106 shares of the biopharmaceutical company’s stock valued at $9,175,000 after purchasing an additional 96,503 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Puma Biotechnology in the 1st quarter valued at approximately $109,000. Kathmere Capital Management LLC increased its stake in Puma Biotechnology by 9.8% in the 1st quarter. Kathmere Capital Management LLC now owns 29,779 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 2,648 shares during the period. Finally, DGS Capital Management LLC purchased a new stake in Puma Biotechnology in the 1st quarter worth approximately $67,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Insider Activity at Puma Biotechnology

In other Puma Biotechnology news, Director Jay M. Moyes sold 22,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.22, for a total value of $158,840.00. Following the sale, the director owned 58,322 shares of the company’s stock, valued at $421,084.84. The trade was a 27.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas M. Hunt sold 8,460 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $8.26, for a total transaction of $69,879.60. Following the completion of the transaction, the insider owned 196,841 shares of the company’s stock, valued at approximately $1,625,906.66. This represents a 4.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 132,028 shares of company stock worth $1,006,711 in the last three months. Company insiders own 22.20% of the company’s stock.

Puma Biotechnology Stock Up 9.7%

Shares of Puma Biotechnology stock opened at $8.91 on Friday. Puma Biotechnology, Inc. has a 12-month low of $3.05 and a 12-month high of $9.40. The stock has a 50 day moving average price of $7.80 and a two-hundred day moving average price of $7.18. The stock has a market capitalization of $453.52 million, a P/E ratio of 17.13 and a beta of 1.22.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.15. The business had revenue of $56.50 million during the quarter, compared to analysts’ expectations of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 21.34%. Sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on PBYI shares. TD Cowen boosted their price target on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a report on Friday. Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings downgraded Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Two analysts have rated the stock with a Hold rating, According to MarketBeat, Puma Biotechnology presently has an average rating of “Hold” and a consensus target price of $6.00.

Trending Headlines about Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.